BIOCAD is a leading Russian innovative biotechnology company, established in 2001, specializing in the research, development, and full-cycle production of original and generic pharmaceuticals. The company focuses on creating advanced medicines, particularly biologics, for treating complex diseases in oncology, immunology, and virology, playing a significant role in the Russian pharmaceutical industry and expanding internationally.

Innovative Drug Development

BIOCAD is recognized for its extensive research and development capabilities, investing heavily in discovering and developing novel therapeutic solutions. Its portfolio includes original biosimilar drugs and innovative gene-engineered biologics. R&D centers employ multidisciplinary teams, focusing on molecular biology, immunology, and bioinformatics to bring cutting-edge treatments to market. This commitment allows BIOCAD to develop high-quality, effective medicines meeting global standards.

Advanced Manufacturing and Market Presence

The company operates state-of-the-art manufacturing facilities in Russia, adhering to international Good Manufacturing Practice (GMP) standards. These facilities enable the full-cycle production of complex biotechnological drugs. BIOCAD's products are distributed across Russia, CIS countries, and exported to markets in Southeast Asia, Latin America, the Middle East, and North Africa, demonstrating its growing global footprint and commitment to making essential medicines accessible.